Société TrovaGene Inc Nasdaq
Actions
US8972383090
Recherche biotechnologique et médicale
Métier
Ventes par activité
USD en Millions | 2022 | Poids | 2023 | Poids | Delta |
---|---|---|---|---|---|
Novel Therapies for Cancers
100,0
%
| 0 | 100,0 % | 0 | 100,0 % | +26,42% |
Ventes par région
USD en Millions | 2022 | Poids | 2023 | Poids | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 0 | 100,0 % | 0 | 100,0 % | +26,42% |
Dirigeants
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Mark Erlander
CEO | Chief Executive Officer | 64 | 04/03/13 |
James Levine
DFI | Director of Finance/CFO | 53 | 12/07/21 |
Tod Smeal
CTO | Chief Tech/Sci/R&D Officer | 59 | 11/01/22 |
Chief Tech/Sci/R&D Officer | - | 31/01/23 | |
Vicki Kelemen
COO | Chief Operating Officer | - | 01/01/15 |
Charles Monahan
LAW | General Counsel | - | 11/01/22 |
Brigitte Lindsay
PRN | Corporate Officer/Principal | - | 01/01/12 |
Administrateurs
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
James Armitage
BRD | Director/Board Member | 77 | 22/04/20 |
Gary Pace
BRD | Director/Board Member | 76 | 22/04/20 |
Mark Erlander
CEO | Chief Executive Officer | 64 | 04/03/13 |
Lâle White
BRD | Director/Board Member | 68 | 22/04/20 |
Mani Mohindru
BRD | Director/Board Member | 52 | 10/06/21 |
Rodney Markin
CHM | Chairman | 67 | 19/02/14 |
Renee Tannenbaum
BRD | Director/Board Member | 72 | 10/06/21 |
Classe d'actions
Vote | Nombre | Flottant | Autocontrôle | Flottant Total | |
---|---|---|---|---|---|
Action A | 1 | 44 724 591 | 41 348 436 ( 92,45 %) | 0 | 92,33 % |
Action B | 0 | 60 600 | 0 | 0 |
Coordonnées société
Cardiff Oncology, Inc.
11055 Flintkote Avenue
92121, San Diego
+858 952 7570
http://www.cardiffoncology.comSecteur
Varia. 1 janv. | Capi. | |
---|---|---|
+17,96% | 44,96 Md | |
+1,17% | 42,65 Md | |
+48,77% | 41,85 Md | |
-4,27% | 29,04 Md | |
+11,42% | 26,08 Md | |
-21,39% | 19,03 Md | |
+4,86% | 12,75 Md | |
+27,29% | 12,06 Md | |
-3,50% | 11,75 Md |